Puma Biotechnology (PBYI) reported $228M in revenue for fiscal 2025, −0.9% year on year. That ranks #2618 by revenue among 2853 SEC filers and #276 in Healthcare. Net income was $31.1M, a net margin of 13.6%. Revenue has grown 30.2% a year on average since 2017 ($27.7M then). The fiscal 2025 balance sheet shows $216M in total assets, $29.6M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $228M | −0.9% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $37.3M | +20.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $31.1M | +2.8% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $41.8M | +7.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $71,000 | +26.8% | FY20252025-12-31 |
| Total assetsAssets | $216M | +1.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $130M | +41.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $29.6M | −57.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $44.8M | −$3.8M | Open → |
| Q2 20262026-06-30 | $56.5M | $8.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Puma Biotechnology, Inc.
- Ticker
- PBYI
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001401667
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| CerusCERS | $234M | −$15.6M |
| TalkspaceTALK | $229M | $7.8M |
| LifevantageLFVN | $229M | $9.8M |
| Puma BiotechnologyPBYI | $228M | $31.1M |
| AxogenAXGN | $225M | −$15.7M |
| Ideaya BiosciencesIDYA | $219M | −$114M |
| Vanda PharmaceuticalsVNDA | $216M | −$221M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Puma Biotechnology — Key figures |url=https://companiesranked.com/en/company/puma-biotechnology |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Puma Biotechnology — Key figures. CompaniesRanked. https://companiesranked.com/en/company/puma-biotechnologyBibTeX
@misc{companiesranked-en-company-puma-biotechnology-2026,
author = {{CompaniesRanked}},
title = {{Puma Biotechnology — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/puma-biotechnology}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001437749-26-005891 · February 26, 2026
{{cite web |title=Puma Biotechnology — Key figures — 10-K (0001437749-26-005891) |url=https://www.sec.gov/Archives/edgar/data/1401667/000143774926005891/pbyi20251231_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.